UCB's Phase III lupus failure casts further shadow over field
This article was originally published in Scrip
Executive Summary
UCB's leading lupus drug, epratuzumab, has failed to meet primary endpoints in two Phase III trials – an event which could deter future investment from this historically tricky development space.